Arteris, Inc. (NASDAQ:AIP – Get Free Report) Director Saiyed Atiq Raza sold 4,907 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $17.00, for a total value of $83,419.00. Following the sale, the director owned 585,093 shares of the company’s stock, valued at $9,946,581. This represents a 0.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Saiyed Atiq Raza also recently made the following trade(s):
- On Friday, February 27th, Saiyed Atiq Raza sold 11,762 shares of Arteris stock. The shares were sold at an average price of $17.01, for a total value of $200,071.62.
- On Thursday, February 26th, Saiyed Atiq Raza sold 73,610 shares of Arteris stock. The stock was sold at an average price of $17.14, for a total value of $1,261,675.40.
Arteris Stock Performance
AIP traded down $0.23 on Friday, reaching $16.99. 519,469 shares of the company’s stock were exchanged, compared to its average volume of 485,938. The company has a market cap of $772.54 million, a price-to-earnings ratio of -20.72 and a beta of 1.47. Arteris, Inc. has a twelve month low of $5.46 and a twelve month high of $19.85. The company’s 50 day moving average is $15.86 and its 200-day moving average is $13.59.
Institutional Investors Weigh In On Arteris
Hedge funds and other institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC acquired a new position in shares of Arteris in the 1st quarter valued at approximately $1,621,000. Strs Ohio acquired a new stake in shares of Arteris during the first quarter worth approximately $104,000. Savant Capital LLC bought a new stake in shares of Arteris in the second quarter worth $97,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Arteris in the second quarter valued at $151,000. Finally, Campbell & CO Investment Adviser LLC bought a new position in Arteris during the 2nd quarter valued at $254,000. 64.36% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research firms have commented on AIP. Weiss Ratings reissued a “sell (d-)” rating on shares of Arteris in a research report on Wednesday, January 21st. Northland Securities set a $24.00 target price on Arteris in a research note on Friday, February 13th. Rosenblatt Securities reissued a “buy” rating and set a $20.00 price target on shares of Arteris in a research report on Friday, February 13th. Finally, TD Cowen restated a “buy” rating on shares of Arteris in a report on Wednesday, November 5th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Arteris has a consensus rating of “Hold” and an average target price of $20.17.
View Our Latest Stock Analysis on Arteris
Arteris Company Profile
Arteris, Inc is a fabless semiconductor intellectual property (IP) company specializing in on-chip interconnect solutions and system IP for advanced integrated circuits. The company’s core products include its FlexNoC network-on-chip (NoC) fabrics, Ncore cache coherent interconnect IP, and CodaCache memory subsystem IP. These technologies enable semiconductor and systems companies to design scalable, energy-efficient chips for applications ranging from automotive and artificial intelligence (AI) to 5G communications and high-performance computing.
Founded in 2003 and headquartered in Santa Clara, California, Arteris serves a global customer base across North America, Europe, and Asia.
Featured Articles
- Five stocks we like better than Arteris
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- This makes me furious
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Arteris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arteris and related companies with MarketBeat.com's FREE daily email newsletter.
